



INDEX

DESCRIPTION

Page

LIST OF FIGURES

i-ii

LIST OF GRAPHS

iii

LIST OF TABLES

iv-vii

ABBREVIATIONS

viii-xii

TABLE OF CONTENTS

CHAPTER DESCRIPTION

I	INTRODUCTION	1-8
II	LITERATURE REVIEW	9-107
2.1	CNS disorders	9-18
2.2	Central Nervous System	19-30
2.3.	Intranasal delivery for brain targeting	31-45
2.4.	Intranasal delivery of peptides	46-49
2.5	Delivery system based approaches or intranasal delivery of drugs	51-53
2.6	Micrioemulsion	54-69
2.7	Mucoadhesive agents	70-72
2.8	Nasal gel	73-74
2.9	Radiolabeling	75-76
2.10	Drugs profile	77-87
2.11	References	88-107
III	ANALYTICAL METHODS	108-126
3.1	Introduction	108
3.2	Materials and Instruments	108
3.3	Methods	109-111
3.4	Experimental conditions	111-114
3.4.1	Clobazam	111-112
3.4.2	Clopidogrel bisulphate\	113-114
3.5	Results	114-122
3.5.1	Clobazam	114-118
3.5.2	Clopidogrel bisulphate	118-122
3.6	Discussion	123-124
3.6.1	Clobazam	123
3.6.2	Clopidogrel bisulphate	124
3.7	References	125-126
IV	FORMULATION AND CHARACTERISATION	127-170
4.1	Introduction	127
4.2	Materials and Instruments	127
4.3	Solubility determination	128
4.4	Preparation of mucoadhesive microemulsion	129-131
4.5	Characterization	132-133

4.6	Nasal toxicity study	134
4.7	Stability study	134-135
4.8	Preparation and characterization of mucoadhesive gel	135-136
4.9	Results	137-161
	4.9.1 Clobazam	137-146
	4.9.2 Clopidogrel bisulphate	146-156
	4.9.3 Insulin like growth factor-1	161
4.10	Discussion	162
	4.10.1 Clobazam	162-165
	4.10.2 Clopidogrel bisulphate	165-168
	4.10.3 Insulin like growth factor-1	168-169
4.11	References	170
V	INVITRO DIFFUSION STUDIES	171-183
5.1	Introduction	171-172
5.2	Materials and methods	172-173
5.3	Invitro diffusion study of formulations	173-174
	5.3.1 Clobazam	173
	5.3.2 Clopidogrel bisulphate	174
5.4	Results	175-178
	5.4.1 clobazam	175-176
	5.4.2 clopidogrel bisulphate	177-178
5.5	Discussion	179-182
	5.5.1 clobazam	179-180
	5.5.2 clopidogrel bisulphate	180-182
5.6	References	183
VI	PHARMACOKINETIC STUDIES	184-214
6.1	Introduction	184
6.2	Materials and formulations	184
6.3	Radiolabeling of formulations and optimization	184
6.4	Biodistribution studies	186-187
6.5	Gamma scintigraphy imaging	187
6.6	Statistical analysis	188
6.7	Results	189-205
	6.7.1 clobazam formulations	189-194
	6.7.2 clopidogrel bisulphate formulations	195-200
	6.7.3 Insulin like growth factor-1 formulations	200-205
6.8	Discussion	206-212
	6.8.1 Clobazam formulations	206-208
	6.8.2 Clopidogrel bisulphate formulations	208-210
	6.8.3 Insulin like growth factor-1 formulations	210-212
6.9	References	213-214
VII	PHARMACODYNAMIC STUDIES	215-229
7.2	Clobazam	215-218
	7.1.1 PTZ induced convulsions in mice	
	7.1.2 Results and Discussion	
7.2	Insulin like growth factor-1	218-222
	7.2.1 Transient global ischemia by carotid artery ligation	

	7.2.2 Results and Discussion	
7.3	Clopidogrel bisulphate	223-226
	7.3.1 Transient global ischemia by carotid artery ligation	
	7.3.2 Results and Discussion	
7.4	References	227-229
VIII	SUMMARY	230-241
XI	CONCLUSION	242-244